Cargando…
Inflammatory Signaling by NOD-RIPK2 Is Inhibited by Clinically Relevant Type II Kinase Inhibitors
RIPK2 mediates pro-inflammatory signaling from the bacterial sensors NOD1 and NOD2, and is an emerging therapeutic target in autoimmune and inflammatory diseases. We observed that cellular RIPK2 can be potently inhibited by type II inhibitors that displace the kinase activation segment, whereas ATP-...
Autores principales: | Canning, Peter, Ruan, Qui, Schwerd, Tobias, Hrdinka, Matous, Maki, Jenny L., Saleh, Danish, Suebsuwong, Chalada, Ray, Soumya, Brennan, Paul E., Cuny, Gregory D., Uhlig, Holm H., Gyrd-Hansen, Mads, Degterev, Alexei, Bullock, Alex N. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4579271/ https://www.ncbi.nlm.nih.gov/pubmed/26320862 http://dx.doi.org/10.1016/j.chembiol.2015.07.017 |
Ejemplares similares
-
Small molecule inhibitors reveal an indispensable scaffolding role of RIPK2 in NOD2 signaling
por: Hrdinka, Matous, et al.
Publicado: (2018) -
Activation loop targeting strategy for design of receptor-interacting protein kinase 2 (RIPK2) inhibitors
por: Suebsuwong, Chalada, et al.
Publicado: (2018) -
Targeting RIPK1,2,3 to combat inflammation
por: Bullock, Alex N., et al.
Publicado: (2015) -
Targeting RIPK1 for the treatment of human diseases
por: Degterev, Alexei, et al.
Publicado: (2019) -
Antioxidant and food additive BHA prevents TNF cytotoxicity by acting as a direct RIPK1 inhibitor
por: Delanghe, Tom, et al.
Publicado: (2021)